Limits...
Development and Evaluation of Dual Cross-Linked Pulsatile Beads for Chronotherapy of Rheumatoid Arthritis.

Bansal AK, Pande V - J Pharm (Cairo) (2012)

Bottom Line: Lornoxicam dual cross-linked beads were prepared by dropping dispersed phase of lornoxicam, pectin, and sodium alginate into the dispersion phase of different concentrations of calcium chloride solution followed by aluminium chloride solution.The formulated beads were further coated by Eudragit L & S 100 in the ratio 1 : 2 w/w in order to achieve desired lag time.In vitro release study showed lag time of 5-8 h before release of lornoxicam from the formulated beads.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, H.R. Patel Institute of Pharmaceutical Education and Research, Dhule, Shirpur 425405, Maharashtra, India.

ABSTRACT
In the present investigation, pulsatile release beads were prepared by ionic gelation technique. Lornoxicam dual cross-linked beads were prepared by dropping dispersed phase of lornoxicam, pectin, and sodium alginate into the dispersion phase of different concentrations of calcium chloride solution followed by aluminium chloride solution. The formulated beads were further coated by Eudragit L & S 100 in the ratio 1 : 2 w/w in order to achieve desired lag time. In vitro release study showed lag time of 5-8 h before release of lornoxicam from the formulated beads. Thus, formulated dual cross-linked beads when administered at bed time may release lornoxicam when needed most for chronotherapeutics of early morning rheumatoid arthritis attacks in chronic patients.

No MeSH data available.


Related in: MedlinePlus

DSC thermograms of (A) lornoxicam (B) lornoxicam, and pectin (C) drug and sodium alginate (D) formulation.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4595973&req=5

fig3: DSC thermograms of (A) lornoxicam (B) lornoxicam, and pectin (C) drug and sodium alginate (D) formulation.

Mentions: DSC analysis of pure drug, physical mixture and formulation are showed in Figure 3. DSC themogram of lornoxicam showed sharp exothermic peak at 232°C due to its melting process (Figure 3(a)). Drug melting peak is present even in its physical mixture with pectin and sodium alginate. However, the small lowering of peak temperature of related enthalpy variation was observed due to the mixture of component. Physical mixture of lornoxicam and pectin, lornoxicam, and sodium alginate showed the peak temperature at 227°C and 234°C (Figures 3(b) and 3(c)). Pectin alginate beads show peak at 235°C (Figure 3(d)). It indicates that no interaction found between drug and polymers.


Development and Evaluation of Dual Cross-Linked Pulsatile Beads for Chronotherapy of Rheumatoid Arthritis.

Bansal AK, Pande V - J Pharm (Cairo) (2012)

DSC thermograms of (A) lornoxicam (B) lornoxicam, and pectin (C) drug and sodium alginate (D) formulation.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4595973&req=5

fig3: DSC thermograms of (A) lornoxicam (B) lornoxicam, and pectin (C) drug and sodium alginate (D) formulation.
Mentions: DSC analysis of pure drug, physical mixture and formulation are showed in Figure 3. DSC themogram of lornoxicam showed sharp exothermic peak at 232°C due to its melting process (Figure 3(a)). Drug melting peak is present even in its physical mixture with pectin and sodium alginate. However, the small lowering of peak temperature of related enthalpy variation was observed due to the mixture of component. Physical mixture of lornoxicam and pectin, lornoxicam, and sodium alginate showed the peak temperature at 227°C and 234°C (Figures 3(b) and 3(c)). Pectin alginate beads show peak at 235°C (Figure 3(d)). It indicates that no interaction found between drug and polymers.

Bottom Line: Lornoxicam dual cross-linked beads were prepared by dropping dispersed phase of lornoxicam, pectin, and sodium alginate into the dispersion phase of different concentrations of calcium chloride solution followed by aluminium chloride solution.The formulated beads were further coated by Eudragit L & S 100 in the ratio 1 : 2 w/w in order to achieve desired lag time.In vitro release study showed lag time of 5-8 h before release of lornoxicam from the formulated beads.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, H.R. Patel Institute of Pharmaceutical Education and Research, Dhule, Shirpur 425405, Maharashtra, India.

ABSTRACT
In the present investigation, pulsatile release beads were prepared by ionic gelation technique. Lornoxicam dual cross-linked beads were prepared by dropping dispersed phase of lornoxicam, pectin, and sodium alginate into the dispersion phase of different concentrations of calcium chloride solution followed by aluminium chloride solution. The formulated beads were further coated by Eudragit L & S 100 in the ratio 1 : 2 w/w in order to achieve desired lag time. In vitro release study showed lag time of 5-8 h before release of lornoxicam from the formulated beads. Thus, formulated dual cross-linked beads when administered at bed time may release lornoxicam when needed most for chronotherapeutics of early morning rheumatoid arthritis attacks in chronic patients.

No MeSH data available.


Related in: MedlinePlus